/assets/production/practices/68edfd341efff207246df8bb02e1b404ebb28019/images/2698850.png)
Treatment of Adults With Moderate to Severe Essential Tremor: Essential tremor (ET) is a neurological disorder that causes your hands, head, trunk, voice or legs to shake rhythmically.
- Participant must be 18 to 80 years of age inclusive, at the time of signing the informed consent.\
/assets/production/practices/68edfd341efff207246df8bb02e1b404ebb28019/images/2698825.jpg)
https://clinicaltrials.gov/study/NCT05122650
(#237) Relapse Remitting Multiple Sclerosis (PTI-307-201 VISTA)
- Subject is fluent in English.
- Male or female 18 to 50 years of age, inclusive, at the first Screening visit.
- A diagnosis of relapsing-remitting multiple sclerosis (RRMS) according to the 2017 Revised McDonald Criteria.
/assets/production/practices/68edfd341efff207246df8bb02e1b404ebb28019/images/2698829.jpg)
https://clinicaltrials.gov/study/NCT06083753?term=PIPE-307&rank=2
(#196) Relapse Remitting Multiple Sclerosis (COMB157GUS09 SOSTOS)
This study will evaluate if relapsing-remitting MS patients that have not had a relapse in the past year would benefit from a switch to ofatumumab (KESIMPTA) versus staying on their continued current therapy.
- Age 18-45 years
- Diagnosis of RRMS per McDonald Criteria (2017)
- EDSS 0-5.5 (Inclusive)
- Able to obtain MRI and attend study visits at sites
- Willing to use wearable device as specified in the protocol
- Able to provide blood sample
- On a current DMT with approved label use for treatment of RRMS at least 6 months prior to Screening
- No relapse reported within 6 months prior to Screening
- Patients may enroll in the trial if they have subclinical disease activity as measured by MRI prior to enrollment. An absence of MRI activity is not exclusionary.
/assets/production/practices/68edfd341efff207246df8bb02e1b404ebb28019/images/2698831.jpg)
https://clinicaltrials.gov/study/NCT05090371
(#384) Relapse Remitting Multiple Sclerosis (BLS-11-404 SIMPLE)
Adult participants with a diagnosis of RRMS who have been receiving continuous treatment with Bafiertam monotherapy per the approved product label for no more than 3 months (90 days) are eligible to enroll in the study. Their satisfaction with Bafiertam treatment will be assessed using a 9-Item Treatment Satisfaction Questionnaire for Medication (TSQM-9). To be included in the study, patients.
- Male or non-pregnant female aged 18 years and older.
- Participants diagnosed with Relapsing forms of multiple sclerosis R(RMS) and satisfy the approved therapeutic indication for Bafiertam per the approved product labeling.
- Participants may enroll if they are within 90 days of initiating therapy with Bafiertam.
/assets/production/practices/68edfd341efff207246df8bb02e1b404ebb28019/images/2698834.jpg)
https://clinicaltrials.gov/study/NCT05978531
https://azneuroscienceresearch.com/